MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

Home・Aandelen Lijst・Altimmune Inc

Altimmune Inc

Gesloten

4.19 9.11

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.77

Max

4.2

Belangrijke statistieken
By Trading Economics
Inkomsten	3.6M -20M
Verkoop	5K
EPS	-0.26
Winstmarge	-391,500
Werknemers	59
EBITDA	2.9M -20M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+478.29% upside

Dividenden
By Dow Jones
Volgende Winsten	7 aug 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	107M 570M
Vorige openingsprijs	-4.92
Vorige sluitingsprijs	4.19

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.365 / 6.0486 Steun & Weerstand

Altimmune Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 jul 2025, 23:09 UTC

Winsten

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 jul 2025, 19:16 UTC

Acquisities, Fusies, Overnames

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 jul 2025, 23:47 UTC

Marktinformatie

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 jul 2025, 23:41 UTC

Marktinformatie

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 jul 2025, 22:23 UTC

Acquisities, Fusies, Overnames

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 jul 2025, 22:23 UTC

Acquisities, Fusies, Overnames

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 jul 2025, 22:21 UTC

Acquisities, Fusies, Overnames

James Hardie Completes Acquisition of AZEK

1 jul 2025, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

1 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

1 jul 2025, 20:24 UTC

Winsten

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 jul 2025, 19:55 UTC

Marktinformatie

Oil Futures Resume Cautious Rally -- Market Talk

1 jul 2025, 19:27 UTC

Marktinformatie

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 jul 2025, 19:12 UTC

Marktinformatie

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 jul 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 jul 2025, 18:41 UTC

Acquisities, Fusies, Overnames

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 jul 2025, 18:33 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

1 jul 2025, 18:33 UTC

Marktinformatie

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 jul 2025, 18:32 UTC

Marktinformatie

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 jul 2025, 18:22 UTC

Marktinformatie

Remittances to Mexico Down in May -- Market Talk

1 jul 2025, 17:45 UTC

Marktinformatie

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 jul 2025, 17:01 UTC

Acquisities, Fusies, Overnames

Danone Completed Acquisition of Majority Stake in Kate Farms

1 jul 2025, 16:55 UTC

Winsten

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 jul 2025, 16:27 UTC

Marktinformatie

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 jul 2025, 16:25 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 jul 2025, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

1 jul 2025, 15:48 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 jul 2025, 15:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

1 jul 2025, 15:46 UTC

Marktinformatie

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 jul 2025, 14:54 UTC

Marktinformatie

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 jul 2025, 14:49 UTC

Marktinformatie

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Peer Vergelijking

Prijswijziging

Altimmune Inc Prognose

Koersdoel

By TipRanks

478.29% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 22.38 USD 478.29%

Hoogste 28 USD

Laagste 12 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Altimmune Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Altimmune Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.365 / 6.0486Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.